Literature DB >> 12171542

Epothilones: a novel class of non-taxane microtubule-stabilizing agents.

Ramin Altaha1, Tito Fojo, Eddie Reed, Jame Abraham.   

Abstract

The epothilones are a novel class of non-taxane microtubule-stabilizing agents obtained from the fermentation of the cellulose degrading myxobacteria, Sorangium cellulosum. Preclinical studies have shown that the epothilones are more potent than the taxanes and active in some taxane-resistant models. Similar to paclitaxel and other taxanes, the epothilones block cells in mitosis, resulting in cell death. The chief components of the fermentation process are epothilones A and B, with epothilones C and D found in smaller amounts. Trace amounts of other epothilones have also been detected. Pre-clinical studies have shown that epothilone B is the most active form, exhibiting significantly higher antitumor activity than paclitaxel and docetaxel. Several phase I and phase II clinical trials are ongoing with epothilone B and BMS 247550, an epothilone B analog. Preliminary reports indicate these agents are active against human cancers in heavily pre-treated patients. The epothilones appear to be well tolerated, with a side effect profile that is similar to that reported with the taxanes. This article will review some basic aspects of epothilone chemistry and biology, and pre-clinical and preliminary clinical experience with epothilone B and its analog, BMS 247550.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12171542     DOI: 10.2174/1381612023394043

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  11 in total

Review 1.  Isolation, biology and chemistry of the disorazoles: new anti-cancer macrodiolides.

Authors:  Chad D Hopkins; Peter Wipf
Journal:  Nat Prod Rep       Date:  2009-03-11       Impact factor: 13.423

2.  From nature to the laboratory and into the clinic.

Authors:  K C Nicolaou; Jason S Chen; Stephen M Dalby
Journal:  Bioorg Med Chem       Date:  2008-11-06       Impact factor: 3.641

3.  Engineering the acyltransferase domain of epothilone polyketide synthase to alter the substrate specificity.

Authors:  Huimin Wang; Junheng Liang; Qianwen Yue; Long Li; Yan Shi; Guosong Chen; Yue-Zhong Li; Xiaoying Bian; Youming Zhang; Guoping Zhao; Xiaoming Ding
Journal:  Microb Cell Fact       Date:  2021-04-21       Impact factor: 5.328

4.  Discovery of new quinolines as potent colchicine binding site inhibitors: design, synthesis, docking studies, and anti-proliferative evaluation.

Authors:  Mohamed Hagras; Moshira A El Deeb; Heba S A Elzahabi; Eslam B Elkaeed; Ahmed B M Mehany; Ibrahim H Eissa
Journal:  J Enzyme Inhib Med Chem       Date:  2021-12       Impact factor: 5.051

Review 5.  Microtubule Organization Is Essential for Maintaining Cellular Morphology and Function.

Authors:  Lijiang Huang; Yan Peng; Xuetao Tao; Xiaoxiao Ding; Rui Li; Yongsheng Jiang; Wei Zuo
Journal:  Oxid Med Cell Longev       Date:  2022-03-07       Impact factor: 6.543

Review 6.  Low Intensity Ultrasound as an Antidote to Taxane/Paclitaxel-induced Cytotoxicity.

Authors:  Celina Amaya; Elizabeth R Smith; Xiang-Xi Xu
Journal:  J Cancer       Date:  2022-04-18       Impact factor: 4.478

7.  Design, eco-friendly synthesis, molecular modeling and anticancer evaluation of thiazol-5(4H)-ones as potential tubulin polymerization inhibitors targeting the colchicine binding site.

Authors:  Abeer M El-Naggar; Ibrahim H Eissa; Amany Belal; Amira A El-Sayed
Journal:  RSC Adv       Date:  2020-01-15       Impact factor: 4.036

8.  Phase II study of first-line sagopilone plus prednisone in patients with castration-resistant prostate cancer: a phase II study of the Department of Defense Prostate Cancer Clinical Trials Consortium.

Authors:  T M Beer; D C Smith; A Hussain; M Alonso; J Wang; M Giurescu; K Roth; Y Wang
Journal:  Br J Cancer       Date:  2012-07-31       Impact factor: 7.640

9.  Human mass balance study of the novel anticancer agent ixabepilone using accelerator mass spectrometry.

Authors:  J H Beumer; R C Garner; M B Cohen; S Galbraith; G F Duncan; T Griffin; J H Beijnen; J H M Schellens
Journal:  Invest New Drugs       Date:  2007-03-09       Impact factor: 3.850

10.  Breaking malignant nuclei as a non-mitotic mechanism of taxol/paclitaxel.

Authors:  Elizabeth R Smith; Xiang-Xi Xu
Journal:  J Cancer Biol       Date:  2021
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.